{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 464382941
| IUPAC_name = ''N'',''N''-dimethyl-2-[5-(1''H''-1,2,4-triazol-1-ylmethyl)-1''H''-indol-3-yl]ethanamine
| image = Rizatriptan.svg
<!--Clinical data-->
| tradename = Maxalt
| Drugs.com = {{drugs.com|monograph|maxalt}}
| MedlinePlus = a601109
| pregnancy_category = B1 <small>([[Australia|Au]])</small>, C <small>([[United States|U.S.]])</small>
| legal_status = Rx-only
| routes_of_administration = Oral
<!--Pharmacokinetic data-->
| bioavailability = 45%
| protein_bound = 14%
| metabolism = by [[monoamine oxidase]]
| elimination_half-life = 2–3 hours
| excretion = 82% [[urine]]; 12% [[faeces]]
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 145202-66-0
| ATC_prefix = N02
| ATC_suffix = CC04
| ATC_supplemental =
| PubChem = 5078
| IUPHAR_ligand = 51
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00953
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4900
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = WR978S7QHH
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = D00675
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 48273
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 905
<!--Chemical data-->
| C=15 | H=19 | N=5
| molecular_weight = 269.345 g/mol
| smiles = n1cncn1Cc2cc3c(cc2)ncc3CCN(C)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C15H19N5/c1-19(2)6-5-13-8-17-15-4-3-12(7-14(13)15)9-20-11-16-10-18-20/h3-4,7-8,10-11,17H,5-6,9H2,1-2H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = ULFRLSNUDGIQQP-UHFFFAOYSA-N
}}
'''Rizatriptan''' (trade name '''Maxalt''') is a [[5-HT1 receptor|5-HT<sub>1</sub> receptor]] [[agonist]] of the [[triptan]] class of [[medication|drugs]] developed by [[Merck & Co.]] for the treatment of [[migraine]] [[headache]]s.<ref name="MedlinePlus">{{cite web|title=Rizatriptan|url=http://www.nlm.nih.gov/medlineplus/druginfo/meds/a601109.html|work=MedlinePlus|publisher=U.S. National Library of Medicine}}</ref> It is available in strengths of 5 and 10 mg as tablets and orally disintegrating tablets (Maxalt-MLT).

Maxalt obtained approval by the United States [[Food and Drug Administration]] (FDA) on June 29, 1998. It is a second-generation triptan.

Rizatriptan is available only by [[Medical prescription|prescription]] in [[Australia]], [[Finland]], the [[United States]], [[Canada]] and [[New Zealand]]. Similarly, it is classed as a POM (Prescription Only Medicine) in the [[United Kingdom]], [[Italy]] (as '''Rizaliv'''), [[France]], [[Israel]] (as '''Rizalt'''), [[Netherlands|The Netherlands]], [[Croatia]] and [[Spain]] (as ''Maxalt'').

==Indications==
Rizatriptan is FDA-approved to treat acute [[migraine]] attacks with or without [[aura (symptom)|aura]]. It does not prevent future migraine attacks.<ref name="MedlinePlus"/> Rizatriptan is also used off-label to treat [[cluster headache]]s.

==Contraindications==
* [[coronary artery disease]]
* use of [[monoamine oxidase inhibitor]]s

==Drug Interactions==
* Monoamine oxidase inhibitors
* [[Propranolol]]<ref name="Millson 2000">{{Cite journal
 | pmid = 11249525
| year = 2000
| author1 = Millson
| first1 = D
| title = Migraine pharmacotherapy with oral triptans: a rational approach to clinical management.
| journal = Expert Opin Pharmacother
| volume = 1
| issue = 3
| pages = 391–404
| last2 = Tepper
| first2 = S
 | doi= 10.1517/14656566.1.3.391
}}</ref>

==Adverse effects==
{{col-begin}}{{col-break}}
Severe:
* [[serotonin syndrome]] when used with [[MAOI]]s
* [[coronary artery]] [[vasospasm]]
* transient [[myocardial ischemia]] {{nb10}}
* [[myocardial infarction]]
* ventricular [[tachycardia]]
* ventricular [[fibrillation]]
* [[hypertension|hypertensive crisis]]

Atypical sensations:
* [[paresthesia]]

[[Cardiovascular]]:
* [[palpitation]]s
* [[Syncope (medicine)|syncope]]
* [[hypertension]]
* [[hypotension]]

Ear, nose, and throat:
* [[tinnitus]]
* [[sinusitis]]
* [[allergic]] [[rhinitis]]
* [[upper respiratory tract]] [[inflammation]]
{{col-break}}
[[Gastrointestinal]]:
* [[diarrhea]]

Muscular:
* [[myalgia]]

Neurological:
* [[phonophobia]]
* [[photophobia]]

Respiratory:
* [[dyspnea]]

Skin:
* [[diaphoresis|sweating]]

Miscellaneous:
* [[hypersensitivity]]
{{col-end}}

==Mechanism of action==
{{main|Serotonin receptor agonist}}
Rizatriptan acts as an agonist at serotonin [[5-HT1B|5-HT<sub>1B</sub>]] and [[5-HT1D|5-HT<sub>1D</sub>]] receptors.<ref name="Wellington 2002">{{Cite journal
 | pmid = 12093318
| year = 2002
| author1 = Wellington
| first1 = K
| title = Rizatriptan: An update of its use in the management of migraine
| journal = Drugs
| volume = 62
| issue = 10
| pages = 1539–74
| last2 = Plosker
| first2 = G. L.
 | doi=10.2165/00003495-200262100-00007
}}</ref> Like the other [[triptans]] [[sumatriptan]] and [[zolmitriptan]], rizatriptan induces [[vasoconstriction]]—possibly by inhibiting the release of [[calcitonin gene-related peptide]] from sensory neurons in the [[trigeminal nerve]].<ref name="Wellington 2002"/>
==References==
{{reflist}}

==External links==
*[http://www.maxalt.com Maxalt] website by [[Merck & Co.]]

{{Triptans}}
{{Serotonergics}}
{{Tryptamines}}
{{Merck&Co}}

[[Category:Merck]]
[[Category:Triazoles]]
[[Category:Triptans]]
[[Category:5-HT1D agonists]]